| 查看: 1770 | 回复: 8 | |||
| 本帖产生 1 个 翻译EPI ，点击这里进行查看 | |||
| 当前只显示满足指定条件的回帖，点击这里查看本话题的所有回帖 | |||
[交流]
一句话求助高人！急啊!（关于临床方面的，英译汉）
|
|||
| The primary efficacy endpoint was the clinical response at the test of cure (TOC) visit in the co-primary populations of the clinically evaluable (CE) and clinical modified intent-to-treat (c-mITT) patients。Sample Text |
回复此楼» 猜你喜欢
导师吐槽：我怎么摊上了这么个极品研究生！
已经有8人回复
-
有多少人是今天查系统知道结果的？
已经有18人回复
-
基金不中，共勉
已经有11人回复
-
麻烦专家们看看评委们的意见（F口面上）
已经有9人回复
-
2026年叶企孙基金
已经有6人回复
-
国自然面上复盘~欢迎讨论
已经有13人回复
-
基金系统什么内容也没有
已经有9人回复
-
为什么资助数各大高校都创新高，自己申请怎么就这么难
已经有11人回复
-
怎么查啊
已经有6人回复
-
哪位高人中了，把查询到的截图贴出来让我看看，让我长长见识
已经有6人回复
| TYGACIL was evaluated in adults for the treatment of complicated skin and skin structure infections (cSSSI) in two randomized, double-blind, active-controlled, multinational, multicenter studies (Studies 300 and 305). These studies compared TYGACIL (100 mg intravenous initial dose followed by 50 mg every 12 hours) with vancomycin (1 g intravenous every 12 hours)/aztreonam (2 g intravenous every 12 hours) for 5 to 14 days. Patients with complicated deep soft tissue infections including wound infections and cellulitis (≥10 cm, requiring surgery/drainage or with complicated underlying disease), major abscesses, infected ulcers, and burns were enrolled in the studies. The primary efficacy endpoint was the clinical response at the test of cure (TOC) visit in the co-primary populations of the clinically evaluable (CE) and clinical modified intent-to-treat (c-mITT) patients. See Table 6. Clinical cure rates at TOC by pathogen in the microbiologically evaluable patients are presented in Table 7. |
7楼2010-11-03 15:24:17
petrocatal
木虫 (正式写手)
- 翻译EPI: 134
- 应助: 23 (小学生)
- 贵宾: 0.01
- 金币: 3436.6
- 红花: 1
- 帖子: 959
- 在线: 299.5小时
- 虫号: 557856
- 注册: 2008-05-13
- 性别: GG
- 专业: 有机化工
2楼2010-11-03 13:09:58
3楼2010-11-03 13:58:57
4楼2010-11-03 13:59:43
投票:
